Evaluation of potentiation of anti-PD-L1 treatment using in vitro models

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14160%2F25%3A00141575" target="_blank" >RIV/00216224:14160/25:00141575 - isvavai.cz</a>

Výsledek na webu

<a href="https://fd2025.sk/assets_congress/fd2025_sk2025/docs/72-nd-czech-slovak-pharmacological-days_1.pdf" target="_blank" >https://fd2025.sk/assets_congress/fd2025_sk2025/docs/72-nd-czech-slovak-pharmacological-days_1.pdf</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Evaluation of potentiation of anti-PD-L1 treatment using in vitro models

Popis výsledku v původním jazyce

Immunotherapy has become one of the most important approaches to cancer treatment. Inhibition of immune system checkpoints, specifically targeting programmed cell death protein and ligand (PD-1, PD-L1), is a key strategy in cancer immunotherapy. Anti-PD-L1 therapy, which blocks the interaction between PD-L1 on tumor cells and PD-1 on T-lymphocytes, can restore immune activity and promote tumor regression. Despite significant clinical success in several cancers, including non-small cell lung cancer, the therapeutic efficacy of anti-PD-L1 therapy remains limited in a subgroup of patients. Therefore, potential strategies to enhance therapeutic response are currently under investigation. Our study focuses on evaluating potentiation of anti-PD-L1 therapy using in vitro models. Namely, two types of co-culture models of activated T-lymphocytes, PD-L1-expressing tumor cell lines and anti-PD-L1 antitumor immunotherapy representative were developed. Their functionality was verified using salicylanilide derivatives. Our co-culture models are of great importance for the study of potentiation of antitumor immunotherapy in vitro.

Název v anglickém jazyce

Evaluation of potentiation of anti-PD-L1 treatment using in vitro models

Popis výsledku anglicky

Immunotherapy has become one of the most important approaches to cancer treatment. Inhibition of immune system checkpoints, specifically targeting programmed cell death protein and ligand (PD-1, PD-L1), is a key strategy in cancer immunotherapy. Anti-PD-L1 therapy, which blocks the interaction between PD-L1 on tumor cells and PD-1 on T-lymphocytes, can restore immune activity and promote tumor regression. Despite significant clinical success in several cancers, including non-small cell lung cancer, the therapeutic efficacy of anti-PD-L1 therapy remains limited in a subgroup of patients. Therefore, potential strategies to enhance therapeutic response are currently under investigation. Our study focuses on evaluating potentiation of anti-PD-L1 therapy using in vitro models. Namely, two types of co-culture models of activated T-lymphocytes, PD-L1-expressing tumor cell lines and anti-PD-L1 antitumor immunotherapy representative were developed. Their functionality was verified using salicylanilide derivatives. Our co-culture models are of great importance for the study of potentiation of antitumor immunotherapy in vitro.

Druh

O - Ostatní výsledky

CEP obor

—

OECD FORD obor

30104 - Pharmacology and pharmacy

Projekt

—

Návaznosti

S - Specificky vyzkum na vysokych skolach

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů